Revolo Biotherapeutics Shares New Preclinical Data Showcasing the Potential of Sublingual ‘1104 in Allergic Disease

Revolo Biotherapeutics notes additionally, the data continues to demonstrate the differentiated upstream MOA of ‘1104, restoring immune homeostasis by impacting both the effector and regulatory arms of the immune system with a persistence of effect for multiple weeks.